[1]谢礼鑫,陈 婷,袁永强.麝香通心滴丸预防心导管术后造影剂所致急性肾损伤的临床研究[J].医学信息,2025,38(08):123-126.[doi:10.3969/j.issn.1006-1959.2025.08.025]
　XIE Lixin,CHEN Ting,YUAN Yongqiang.Clinical Study of Shexiang Tongxin Dropping Pills on Prevention of Contrast-induced Acute Kidney Injury After Cardiac Catheterization[J].Journal of Medical Information,2025,38(08):123-126.[doi:10.3969/j.issn.1006-1959.2025.08.025]
点击复制

麝香通心滴丸预防心导管术后造影剂所致急性肾损伤的临床研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
38卷
期数:
2025年08期
页码:
123-126
栏目:
论著
出版日期:
2025-04-15

文章信息/Info

Title:
Clinical Study of Shexiang Tongxin Dropping Pills on Prevention of Contrast-induced Acute Kidney Injury After Cardiac Catheterization
文章编号:
1006-1959（2025）08-0123-04
作者:
谢礼鑫; 陈 婷; 袁永强
上犹县人民医院心内科，江西 上犹 341200
Author(s):
XIE Lixin;  CHEN Ting;  YUAN Yongqiang
Department of Cardiology, Shangyou County People’s Hospital, Shangyou 341200, Jiangxi, China
关键词:
麝香通心滴丸; 心导管术; 造影剂; CI-AKI
Keywords:
Shexiang Tongxin dropping pills;  Cardiac catheterization;  Contrast agent;  CI-AKI
分类号:
R541.4
DOI:
10.3969/j.issn.1006-1959.2025.08.025
文献标志码:
A
摘要:
目的 研究麝香通心滴丸预防心导管术后造影剂所致急性肾损伤（CI-AKI）的效果。方法 选取2022年1月-2023年11月就诊于我院拟行冠状动脉造影或经皮冠脉介入术的402例患者为研究对象，采用随机数字表法分为对照组和试验组，各组201例。试验组入院当天开始口服麝香通心滴丸，对照组不予以口服麝香通心滴丸，比较两组术后急性肾损伤发生率、肾功能指标、炎症因子指标、肾动脉阻力指数（RRI）、不良心脏事件发生率。结果 试验组CI-AKI发生率（3.48%）低于对照组（16.42%）（P＜0.05）；两组血肌酐（SCr）、尿素氮（BUN）均高于术前，肾小球滤过率（eGFR）均低于术前，但试验组SCr、BUN均低于对照组，eGFR高于对照组（P＜0.05）；两组C反应蛋白（CRP）、肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）均高于术前，但试验组低于对照组（P＜0.05）；两组RRI均高于术前，但试验组低于对照组（P＜0.05）；随访3个月，试验组不良心脏事件发生率（1.99%）与对照组（2.99%）比较，差异无统计学意义（P＞0.05）。结论 麝香通心滴丸在预防心导管术后造影剂所致CI-AKI中效果确切，可抑制炎症反应，减轻肾损伤，降低CI-AKI发生率。
Abstract:
Objective To study the effect of Shexiang Tongxin dropping pills on the prevention of contrast-induced acute kidney injury (CI-AKI) after cardiac catheterization. Methods A total of 402 patients who underwent coronary angiography or percutaneous coronary intervention in our hospital from January 2022 to November 2023 were selected as the research objects. They were divided into control group and experimental group by random number table method, with 201 patients in each group. The experimental group began to take Shexiang Tongxin dropping pills orally on the day of admission, while the control group did not take Shexiang Tongxin dropping pills orally. The incidence of acute kidney injury, renal function index, inflammatory factor index, renal artery resistance index (RRI) and incidence of adverse cardiac events were compared between the two groups. Results The incidence of CI-AKI in the experimental group (3.48%) was lower than that in the control group (16.42%) (P<0.05). The serum creatinine (SCr) and urea nitrogen (BUN) in the two groups were higher than those before operation, and the glomerular filtration rate (eGFR) was lower than that before operation, but the SCr and BUN in the experimental group were lower than those in the control group, and the eGFR was higher than that in the control group (P<0.05). The levels of C-reactive protein (CRP), tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in the two groups were higher than those before operation, but those in the experimental group were lower than the control group (P<0.05). The RRI of the two groups was higher than that before operation, but that of the experimental group was lower than that of the control group (P<0.05). After 3 months of follow-up, there was no significant difference in the incidence of adverse cardiac events between the experimental group (1.99%) and the control group (2.99%) (P>0.05). Conclusion Shexiang Tongxin dropping pills is effective in preventing CI-AKI caused by contrast agent after cardiac catheterization, which can inhibit inflammatory reaction, reduce renal injury and the incidence of CI-AKI.

参考文献/References:

[1]高伟勤,赵婉晴,杨军.心脏康复治疗对AMI患者PCI术后预后的影响[J].心血管康复医学杂志,2020,29(4):406-409.[2]Samsky MD,Morrow DA,Proudfoot AG,et al.Cardiogenic shock af ter acute myocardial infarction:a review[J].JAMA,2021,326(18):1840-1850.[3]杨坤,陈剑飞,刘林琼,等.急诊PCI术后急性造影剂相关性肾损伤发生情况及其影响因素分析[J].临床急诊杂志,2021,22(6):390-394.[4]任良强,侯晓晓,乔平,等.WMR、RDW、NLR水平与急性心肌梗死 患者PCI术后发生主要不良心血管事件的关系[J].中国现代医学杂志,2022,32(2):74-79. [5]范春炜,陈璟,车春香,等.BNP/NT-proBNP在老年心力衰竭患者心功能评估中的应用价值[J].中华临床医师杂志,2020,14(6):439-443.[6]于承暄,郭代红,贾王平,等.22904例住院患者碘造影剂致急性肾损伤临床特征及相关危险因素分析[J].中国医院药学杂志,2021,41(12):1229-1233,1238.[7]张青霞,于博然.急性冠脉综合征患者冠脉介入术后对比剂肾损伤的危险因素[J].实用药物与临床,2020,23(1):43-46.[8]张洁,王晓红,杨华,等.急性心肌梗死部位及NT-pro BNP水平与STEMI患者行PCI后CI-AKI发生率的关系及意义研究[J].临床和实验医学杂志,2022,21(12):1254-1258.[9]赵汉如,侯丽芳,周单,等.心电图联合血清氨基末端脑钠肽前体对急性心肌梗死患者择期经皮冠状动脉介入治疗后近期发生主要不良心血管事件的预测价值研究[J].实用心脑肺血管病杂志,2021,29(4):32-37,44.[10]陈骥,伍海斌,孙小聪,等．肾动脉阻力指数对脓毒症相关性急性肾损伤可逆性诊断的预测价值[J]．广东医学,2019,40(13):1971-1973．[11]施超,周玉杰,秦政,等.急性冠状动脉综合征合并糖尿病患者急诊经皮冠状动脉介入术后对比剂急性肾损伤的危险因素分析[J].心肺血管病杂志,2018,37(5):393-397.[12]Vlachopanos G,Schizas D,Hasemaki N,et al.Pathophysiology of Contrast-Induced Acute Kidney Injury (CIAKI)[J].Curr Pharm Des,2019,25(44):4642-4647.[13]马丽娅,李震,沈亚琪,等.碘对比剂相关急性肾损伤及相关危险因素的大样本回顾性研究[J].放射学实践,2018,33(9):918-922.[14]汪念东,徐先进,农彦林,等.阿托伐他汀对老年冠心病患者PCI术后造影剂肾病的影响[J].疑难病杂志,2019,18(1):31-34.[15]武强,林欣,缪晓帆,等.甲花片对冠状动脉造影或介入治疗后造影剂肾病患者肾损伤指标的影响[J].南京中医药大学学报,2020,36(2):189-192.[16]王大鹏,闫红霞,周立宾,等.金水宝胶囊联合瑞舒伐他汀治疗经皮冠状动脉介入治疗术后并发造影剂肾病临床观察[J].中国药业,2020,29(16):90-92.[17]唐婷,麦李明,陈曦,等.强化阿托伐他汀防治经皮冠状动脉介入术后造影剂肾病的效果及对炎症应激反应的影响[J].川北医学院学报,2021,36(8):1015-1018.[18]冯俊,余世成,孙召金,等.重组人脑利钠肽对老年急性心肌梗死患者直接介入术后预防造影剂肾病的保护作用[J].中华老年心脑血管病杂志,2021,23(5):487-490.[19]林欣,王一如,缪晓帆,等.甲花片防治冠状动脉介入术患者造影剂肾病的临床研究[J].现代中西医结合杂志,2020,29(35):3882-3885.[20]陈晓扬,张曦元,姚姗姗,等.不同剂量二甲双胍对行直接经皮冠状动脉介入治疗患者造影剂肾病发病率的影响[J].实用医学杂志,2020,36(20):2834-2837.[21]玄进,李振勇.五苓散联合前列地尔预防冠心病患者经皮冠状动脉介入术后造影剂肾病发生率的影响[J].辽宁中医杂志,2020,47(9):83-86.[22]于江,肖虹,刘宇.中医证型分布与冠状动脉介入术后造影剂肾病的相关性研究[J].中国中医急症,2021,30(2):227-229,277.[23]王飞飞,潘立栋.通心络胶囊联合美托洛尔对老年缺血性心肌病合并心力衰竭患者的临床疗效及安全性观察[J].贵州医药,2022,46(4):616-618.

相似文献/References:

[1]秦娅玲,宋 萍.心导管术的ICD-9-CM-3编码探讨及案例分析[J].医学信息,2020,33(19):16.[doi:10.3969/j.issn.1006-1959.2020.19.005]
　QIN Ya-ling,SONG Ping.Discussion and Case Analysis of ICD-9-CM-3 Coding in Cardiac Catheterization[J].Journal of Medical Information,2020,33(08):16.[doi:10.3969/j.issn.1006-1959.2020.19.005]

更新日期/Last Update: 1900-01-01